There is so much debate about clinical pathways. Some propose that they are an excellent way to reduce variability in clinical care and reduce cost, but others contend that they take away from the clinical judgment and bind physicians into algorithms that do not represent all the patients they care for.
To discuss the pros and cons of clinical pathways, I interviewed Bobby Daly, MD, MBA from Memorial Sloan Kettering Cancer Center. Bobby breaks down prevalent touch points in oncology clinical pathways, including conflicts of interest on pathway development panels, potential for cost variation due to site of care, and interoperability challenges between vendor pathways and individual EMRs.
This podcast is produced by the Journal of Clinical Pathways.
Dr. Joe Mikhael, Chief Medical Officer of the International Myeloma Foundation (IMF) and Professor at TGen, takes us beyond his medical career to explore the personal experiences that have shaped his journey in oncology. Dr. Mikhael discusses the IMF’s targeted strategies for reducing health disparities among diverse ethnic and racial groups affected by myeloma, shedding
Tom Beer, Chief Medical Officer of the Multi-Cancer Early Detection (MCED) program at Exact Sciences, delves into the groundbreaking science behind MCED tests, which use advanced biomarkers for early detection of multiple cancer types. On this Healthcare Unfiltered episode, he explains who may be eligible for these tests, how to interpret results to avoid unnecessary
In this special episode, I give up the microphone to guest host Kelly Ryerson, who takes over the show asking questions about my new book “The Cancer Journey.”
